Cilengitide

Generic Name: Cilengitide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀N_₈O_₇

CAS Number: 188968-51-6

Unique Ingredient Identifier: 4EDF46E4GI

Background: Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Phase 2

Withdrawn

Conditions: Glioblastoma

Interventions: Drug: Cilengitide
Drug: Bevacizumab
Behavioral: Questionnaire

First Posted Date: 2013-02-04

Last Posted Date: 2018-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01782976

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

Phase 2

Terminated

Conditions: Gliomas

Interventions: Drug: Cilengitide
Drug: Temozolomide

First Posted Date: 2012-01-25

Last Posted Date: 2015-07-21

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 28

Registration Number: NCT01517776

Locations: 🇩🇪
University Children´s Hospital, Halle, Saxonia-Anhalt, Germany

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Estrogen Receptor Negative
HER2/Neu Negative
Male Breast Carcinoma
Stage IIIB Breast Cancer
Stage IV Breast Cancer
Adult Solid Neoplasm
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Triple-Negative Breast Carcinoma
Stage IIIC Breast Cancer

Interventions: Drug: Cilengitide
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study

First Posted Date: 2011-01-13

Last Posted Date: 2016-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT01276496

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

Phase 1

Completed

Conditions: Diffuse Intrinsic Pontine Glioma

Interventions: Drug: Cilengitide dose escalation
Drug: Cilengitide
Radiation: Concomitant radiotherapy
Biological: Pharmacokinetic
Biological: Pharmacogenetic
Biological: Exploratory investigation

First Posted Date: 2010-07-19

Last Posted Date: 2016-02-17

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 32

Registration Number: NCT01165333

Locations: 🇫🇷
Hôpital des Enfants, Groupe Hospitalier, Bordeaux, France
🇫🇷
Centre Hospitalier Universitaire de Nantes, Nantes, France
🇫🇷
Centre Léon Bérard, Lyon, France

and more 6 locations

Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene

Phase 2

Conditions: Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4

First Posted Date: 2010-05-17

Last Posted Date: 2011-07-26

Lead Sponsor: Northern Sydney and Central Coast Area Health Service

Target Recruit Count: 48

Registration Number: NCT01124240

Locations: 🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Phase 1

Terminated

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Solid Neoplasm
Recurrent Adult Brain Neoplasm

Interventions: Other: Clinical Observation
Drug: Cilengitide
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-05-13

Last Posted Date: 2015-04-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT01122888

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Phase 1

Completed

Conditions: Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Giant Cell Glioblastoma

Interventions: Drug: Cediranib Maleate
Drug: Cilengitide
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-09-18

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00979862

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

and more 8 locations

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
Brain and Central Nervous System Tumors

Interventions: Drug: cilengitide
Other: pharmacological study
Radiation: radiation therapy

First Posted Date: 2009-04-21

Last Posted Date: 2024-05-10

Lead Sponsor: Universitätsmedizin Mannheim

Target Recruit Count: 19

Registration Number: NCT00884598

Locations: 🇩🇪
University Medical Center, Department of Surgery, Mannheim, Germany

Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cilengitide
Drug: Cetuximab
Drug: Cisplatin
Drug: Chemotherapy
Drug: Vinorelbine
Drug: Gemcitabine

First Posted Date: 2009-02-12

Last Posted Date: 2017-01-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 232

Registration Number: NCT00842712

Locations: 🇪🇸
Research Site, Barcelona, Spain

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

Phase 3

Completed

Conditions: Glioblastoma

Interventions: Drug: Cilengitide
Drug: Temozolomide
Radiation: Radiotherapy

First Posted Date: 2008-06-03

Last Posted Date: 2014-11-04

Lead Sponsor: EMD Serono

Target Recruit Count: 545

Registration Number: NCT00689221

Locations: 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪
Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy